Stockscreener 앱 받기
0.0739
37.11%
-0.0436
전일 마감가:
$0.1175
열려 있는:
$0.0927
하루 거래량:
39.74M
Relative Volume:
40.95
시가총액:
$2.31M
수익:
$680.00K
순이익/손실:
$-75.33M
주가수익비율:
-0.0119
EPS:
-6.1898
순현금흐름:
$-57.38M
1주 성능:
-59.26%
1개월 성능:
-91.41%
6개월 성능:
-95.52%
1년 성능:
-97.93%
1일 변동 폭
$0.069
$0.0935
1주일 범위
$0.069
$0.197
52주 변동 폭
$0.069
$4.29
바이오엑셀 테라퓨틱스 Stock (BTAI) Company Profile
명칭
Bioxcel Therapeutics Inc
전화
203-643-8060
주소
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
0.0739 | 25.00M | 680.00K | -75.33M | -57.38M | -6.1898 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
바이오엑셀 테라퓨틱스 Stock (BTAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 개시 | Rodman & Renshaw | Buy |
| 2024-02-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-08-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-07-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-01 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-06 | 재확인 | BofA Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-30 | 개시 | Goldman | Buy |
| 2020-09-02 | 개시 | Jefferies | Buy |
| 2020-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-04 | 개시 | Guggenheim | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
모두보기
바이오엑셀 테라퓨틱스 주식(BTAI)의 최신 뉴스
ARMISTICE CAPITAL, LLC Reduces BioXcel Therapeutics Inc (BTAI) S - GuruFocus
BioXcel Therapeutics Faces August 21 Oaktree Transaction Deadline As $13.8 Million Cash Funds Operations Only Through August - Pulse 2.0
BioXcel (BTAI) Session Check: Ends Down by 11.01% at $0.79; Chart Reference: the $0.75 to $0.83 Range Remains in Focus on the DayCatalyst Driven Stocks - vinanet.vn
BioXcel Therapeutics Inc (NASDAQ: BTAI) Share Price, BTAI Stock News, BTAI Share Price & Updates - Kalkine
BioXcel Shareholder Notice - TMX Newsfile
BioXcel Therapeutics earnings missed by $0.07, revenue fell short of estimates - Investing.com
BioXcel Therapeutics (BTAI) director receives option grant for 17,000 shares - Stock Titan
BioXcel Therapeutics (BTAI) files Form 3 for new director Susan E. Atkins - Stock Titan
Bioxcel Therapeutics Stock Price Forecast. Should You Buy BTAI? - StockInvest.us
Armistice Capital (BTAI) discloses 4.99% BioXcel Therapeutics stake via managed fund - Stock Titan
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
BioXcel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BioXcel Therapeutics (BTAI) flags going concern risk with high debt and cash strain - Stock Titan
BioXcel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BTAI Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares Rally 7.08%Guidance Upgrade Report - vinanet.vn
BioXcel Deadline Alert - TMX Newsfile
BioXcel Therapeutics (BTAI) Earnings Date and Reports 2026 $BTAI - MarketBeat
BioXcel Therapeutics Wins Liquidity Relief as Oaktree Cuts Minimum Cash Covenant to $3 Million - Minichart
BioXcel amends Oaktree-led credit agreement, cuts minimum liquidity covenant to $3 million - Bitget
BioXcel Therapeutics Amends Oaktree Credit Pact, Extends Deal Deadline and Lowers Liquidity Floor - TradingView
BioXcel Therapeutics (BTAI) cuts liquidity covenant, faces August 2026 refinancing deadline - Stock Titan
BioXcel Therapeutics, Inc. Enters Into Twelfth Amendment To Credit Agreement And Guaranty And First Amendment To Security Agreement - marketscreener.com
BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill
BTAI Q2'26 Earnings: EPS estimate is (0.44) USD - TradingView
BioXcel Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
BioXcel Therapeutics Inc (BTAI) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
BioXcel Therapeutics (BTAI) Gains 6.3% to $0.88 as Buyers Defend SupportSector ETF Flow - vinanet.vn
BioXcel Therapeutics (BTAI) Tests Key Support at $0.84 as Biotech Selloff ContinuesAnchored VWAP - dars.gov.et
BioXcel Shareholder Action Reminder - TMX Newsfile
BTAI Q2'26 Earnings: revenue estimate is 484.63K USD - TradingView
BioXcel Therapeutics Wins Deferral on $9.0M Payment, Liquidity Covenant Cut to $6.25M Under Oaktree Deal - TradingView
BioXcel Therapeutics (NASDAQ: BTAI) defers $9.0M payment, lowers liquidity covenant - Stock Titan
BTAI|BioXcel Therapeutics Inc|Price:0.830|Chg%:-0.011 - TradingKey
BioXcel Therapeutics Inc (BTAI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BTAI|BioXcel Therapeutics Inc|Price:1.180|Chg%:+0.050 - TradingKey
BioXcel Therapeutics Inc (BTAI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioXcel Therapeutics Market Sentiment - Benzinga España
BTAI|BioXcel Therapeutics Inc|Price:0.870|Chg%:+0.022 - TradingKey
BioXcel Therapeutics Inc (BTAI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
BioXcel Therapeutics, Inc. Revenue Breakdown – MUN:BX20 - TradingView
BioXcel Therapeutics Inc (BTAI) Balance Sheet - TradingKey
TradingKey - TradingKey
BTAI Q1 2026 Earnings: Narrower Loss Surprises, But Revenue Remains AbsentEPS Consistency Score - dars.gov.et
BioXcel Therapeutics Inc (BTAI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BTAI Q1 2026 Earnings: EPS Surpasses Estimates Amid Ongoing Pipeline DevelopmentRevenue Inflection Point - vinanet.vn
[Latest] Global AI in Drug Repurposing Market Size/Share Worth USD 10.56 Billion by 2035 at a 23.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
BioXcel Therapeutics Q1 2026 Earnings: EPS Beats Estimates by 35.72% Amid Continued Cost ManagementShare Dilution Risk - dars.gov.et
BioXcel Therapeutics Inc. (BTAI) Q1 2026 Earnings: EPS Beats Estimates as Loss Narrows Despite Missing Revenue MilestoneDividend Earnings Report - dars.gov.et
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
BioXcel Therapeutics (BTAI) Rallies 7.9% as Biotech Stock Tests Key Resistance at $0.92ALMA Signal - dars.gov.et
BioXcel Therapeutics (BTAI) Investor update Summary - Quartr
바이오엑셀 테라퓨틱스 (BTAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오엑셀 테라퓨틱스 주식 (BTAI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rodriguez Javier | See Remarks |
May 20 '26 |
Sale |
1.08 |
6,560 |
7,111 |
26,803 |
| Steinhart Richard I | Chief Financial Officer |
May 20 '26 |
Sale |
1.08 |
6,845 |
7,427 |
26,300 |
| Mehta Vimal | CEO and President |
May 20 '26 |
Sale |
1.09 |
19,419 |
21,108 |
69,598 |
1.66%
0.33%
자본화:
|
볼륨(24시간):